This compound has a stronger human clinical evidence base than typical research peptides, but it still requires clinician oversight and approved-use context.
Overview
Liraglutide is an FDA-approved GLP-1 receptor agonist, prescribed as Victoza (type 2 diabetes) and Saxenda (weight management). It's the once-daily predecessor to weekly agents like semaglutide.
How It's Thought to Work
Like other GLP-1 agonists, it stimulates insulin release, slows gastric emptying, and reduces appetite.
What the Research Says
Backed by large human clinical trial programs (LEAD for diabetes, SCALE for obesity) and cardiovascular outcome data.
Key studies to start with
Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review
Medical sciences (Basel, Switzerland) · 2026 Oct 9
PubMedGenetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner
Life sciences · 2026 Oct 26
PubMedMusculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System
Cureus · 2026 Sep
Regulatory & Legal Status
FDA-approved and prescription-only. Compounded/counterfeit versions are a safety concern.
Safety Considerations
Common GI side effects; important warnings and contraindications apply. Use only under a prescribing clinician.